Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 211
- Registration Number
- NCT03069352
- Locations
- 🇺🇸
H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States
🇺🇸Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States
🇦🇷Cemic /Id# 159676, Buenos Aires, Argentina
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Molly Gallogly
- Target Recruit Count
- 65
- Registration Number
- NCT03064867
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 37
- Registration Number
- NCT03063944
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 67
- Registration Number
- NCT03054896
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 22
- Registration Number
- NCT03045328
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
🇺🇸City of Hope, Duarte, California, United States
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT03041688
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 31
- Registration Number
- NCT03036904
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03000660
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000257
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States
🇺🇸The University of Chicago Medical Center /ID# 157375, Chicago, Illinois, United States
🇺🇸Virginia Cancer Specialists - Fairfax /ID# 157377, Fairfax, Virginia, United States
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 443
- Registration Number
- NCT02993523
- Locations
- 🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 162534, Atlanta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 201133, Chicago, Illinois, United States
🇺🇸University of Chicago Medicine /ID# 154108, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.